Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Authors: Matthew Ho, Alon Lazarovich, Ragheed Saoud, Aaron Dahmen, Samuel Tremblay, Siobhan Telfer, Mahir Maruf, Eric A. Singer, Robert E. Weiss, Thomas L. Jang, Sammy E. Elsamra, Maria Merino, Rebecca Dolan, Vladimir Valera, Beatriz Walter Rodriquez, Reema Railkar, Sonia Bellfield, Lambros Stamatakis, Joanna Shih, Renee N. Donahue, Cesar Pico Navarro, Andrea B. Apolo, James L. Gulley, Jeffrey Schlom, Piyush K. Agarwal
Institutions: University of Chicago, Northwell Health, Arthur Smith Institute for Urology, University of Pittsburgh Medical Center, University of Michigan, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Rutgers Cancer Institute, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Frederick National Laboratory for Cancer Research, MedStar Georgetown University Hospital, Bavarian Nordic (United States)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G330876103, G6374948078
OpenAlex ID: W4413055153